Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 1616

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Disease
  • DNA
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1616

License Grant
Licensor hereby grants to Licensee an exclusive license in the Licensed Fields under the Licensed Patents to practice any Licensed Process and to make and have made Licensed Products.
License Property
Licensed Patents  Invention Safe Vector for Gene Therapy

Product manufacture, use or sale of vectors or virions solely for use in the genetic alteration of mammalian cells taken from a donor, which cells are to be reintroduced into such donor or introduced into a single, pre-identified human host.  Additional property includes the manufacture, use or sale of vectors, virions or cells transformed or transfected with vectors or virions, or the progeny of such cells, which vectors, virions or cells are intended solely for direct administration into a human for therapeutic or diagnostic purposes only by the ultimate user of such product.

Field of Use
Licensed Field I shall mean the manufacture, use or sale of vectors or virions solely for use only by the ultimate user in the genetic alteration of mammalian cells taken from a donor which cells are to be reintroduced into such donor or introduced into a single, pre-identified human host.

Licensed Field shall mean the manufacture, use or sale of vectors, virions or cells transformed or transfected with vectors or virions, or the progeny of such cells, which vectors, virions or cells are intended solely for direct administration into a human for therapeutic or diagnostic purposes only by the ultimate user of such product.

IPSCIO Record ID: 240466

License Grant
The Licensor of England grants to the Licensee the following licenses under the Winter Patent
– a non-exclusive world-wide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed.
– a non-exclusive sub-license under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process to produce Products from mammalian cells and for no other purpose.
License Property
Licensor has certain patent rights in respect of the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another.

The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.

The Products shall mean end products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis.

Winter patents relate to Recombinant DNA products and Methods.

Boss patents relate to Multichain Polypeptides or Proteins and Processes for their Production Expression of multichain proteins, such as antibodies, in single hose cells.

Field of Use
The Fields shall mean the field of human therapy or prophylaxis and human in vivo and in vitro diagnostics.

IPSCIO Record ID: 294014

License Grant
Licensor, a medical research centers, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
The patents and patent applications relate to Modified Adena-Associated Virus Vector Capable of Expression from a Novel Promoter.

Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

Field of Use
The field of use is the development of compositions and methods utilizing Adeno-Associated Viral Vectors embodied in the Licensed Patent Rights which are useful in the treatment and prophylaxis of human and animal diseases, and does not include compositions and methods for the treatment and prophylaxis of cystic fibrosis.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.